


a compound having the following formula:



(1)
cont.

or a prodrug derivative thereof, wherein G₁ is selected from the group consisting of (C₁-C₆)alkyl, (C₁-C₆)alkenyl, aryl group or a heteroaryl group, wherein the aryl or heteroaryl is a ring having 5, 6 or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, wherein G₂ is a group having a neutral or a net charge, selected from the following: -CN(R₁R₂R₃), -CN(R₁R₂), -N(R₁R₂R₃), -N(R₁R₂), or a heteroaryl group, wherein the heteroaryl is a ring having 5, 6 or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, wherein R₁, R₂ and R₃ independent of one another are selected from the group consisting of -H, -CH₃, -CH₂CH₃ or other linear alkyl groups such as propyl, butyl, or pentyl, wherein G₃ and G₄ independent of one another are selected from the group consisting of N, S, O, (C₁-C₆)alkyl, and (C₁-C₆)alkenyl, wherein X is a (C₁-C₁₂)alkyl and wherein Z is present as a charged species when G₂ has a net charge, the charge of Z depends on the charge of G₂, Z is absent when G₂ is neutral in charge; and

C
cont.

a pharmaceutically acceptable carrier.

C 2
2. (Thrice Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of N-ethyl-N'-(3-dimethylaminopropyl) urea or a salt thereof in combination with a pharmaceutically acceptable solid carrier.

C 3
72. (Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of N-ethyl-N'-(3-dimethylaminopropyl) urea or a salt thereof in combination with a pharmaceutically acceptable sterile liquid carrier.

C 4
74. (Amended) A pharmaceutical composition comprising an aerosol form of a pharmaceutically effective amount of N-ethyl-N'-(3-dimethylaminopropyl) urea or a salt thereof.

Please add the following new claim:

C 5
75. (New) The pharmaceutical composition of claim 72 wherein the pharmaceutically acceptable sterile liquid carrier is isotonic.

REMARKS

Applicants appreciate the Examiner's review of the present application and respectfully requests reconsideration in view of the preceding amendments and the following remarks. Claims 1-74 are pending in the application. Claims 1 and 3-71 are withdrawn from consideration based on Applicants' election in response to the Examiner's restriction requirement. Claim 73 has been cancelled; claim 75 has been added; claims 1, 2, 72 and 74 have been amended in the present amendment. Support for the amended and newly added claims can be found throughout the specification. More specifically, support for the recitation of "neutral" form of compound in claim